ArticleBMC public health2021
Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
Article in BMC public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Analysis of outcomes of nab-paclitaxel compared to other taxanes in early breast cancer: A study revealing the critical role of calendar-time bias in real-world drug comparisons.Breast (Edinburgh, Scotland) · 2026Article
- Drug price trends, regional disparities, and supply shortages under China's National Volume-Based Procurement: a nationwide analysis (2018-2024).BMC health services research · 2026Article
- Analysis of drug use and expenditure of conventional and biological disease-modifying anti-rheumatic drugs: a study from Northwest China.Clinical rheumatology · 2026Article
- Changes in the burden of lower respiratory infections in China before and after the implementation of the national centralized drug procurement policy.Infectious medicine · 2026Article
- The differential impact of Diagnosis-Related Groups (DRG) on hierarchical hospitals: an interrupted time series analysis on health expenditure structure.BMC health services research · 2026Article
- Impact of centralized volume-based procurement of high-value medical consumables on patients' hospitalization expenses in Gansu, China: an interrupted time series analysis.BMC health services research · 2026Article
- Cost-effectiveness of omadacycline versus moxifloxacin as the initial treatment for community-acquired bacterial pneumonia in China.International journal of clinical pharmacy · 2026Article
- Drug-cost trajectories after national volume-based procurement in Chinese public hospitals: a 31-province interrupted time-series analysis.Frontiers in medicine · 2026Article
- Knowledge, attitudes, and practices of outpatients regarding National centralized drug procurement policy: a multicenter cross-sectional study in North China.Scientific reports · 2025Article
- Changes in Clinical Trials of Dermatological Drugs in Mainland China Between 2016 and 2022: A Narrative Review.Therapeutic innovation & regulatory science · 2025Review
- Intended and Unintended Impacts of '4+7' Volume-Based Drug Procurement on the Use of Drugs in China: A Natural Experimental Study.Healthcare (Basel, Switzerland) · 2025Article
- Healthcare professionals' knowledge, attitudes, and practices regarding China's National Centralized Drug Procurement policy: a cross-sectional study in Shaanxi Province.Frontiers in public health · 2025Article
- Pharmaceutical expenditure changes under the volume-based procurement policy: Effects and influencing factors.PloS one · 2025Article
- Article
- Will centralized drug procurement policy improve enterprises' total factor productivity?Frontiers in public health · 2025Article
- Comparative study on government subsidy models for competitive drug supply chains under centralized procurement policy.Frontiers in public health · 2025Article
- Increased consumption of cardiovascular drugs under volume-based procurement (VBP) policy: demand release or assessment inducing?Health research policy and systems · 2024Article
- Article
- Whether medicine supply is really meeting primary health care needs: a mixed-methods study in Shandong Province, China.Global health research and policy · 2024Article
- The vacated space of volume/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China.BMC health services research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Chinese government implemented the first round of National Centralized Drug Procurement (NCDP) pilot (so-called "4 + 7" policy) in mainland China in 2019. This study aims to examine the impact of "4 + 7" policy on the price of policy-related drugs.
methodsThis study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. "4 + 7" policy-related drugs were selected as study samples, including 25 drugs in the "4 + 7" procurement list and 57 alternative drugs that have an alternative relationship with "4 + 7" List drugs in clinical use. "4 + 7" List drugs were then divided into bid-winning and bid-non-winning products according to the bidding results. Single-group Interruption Time Series (ITS) analysis was adopted to examine the change of Drug Price Index (DPI) for policy-related drugs.
resultsThe ITS analysis showed that the DPI of winning (- 0.183 per month, p < 0.0001) and non-winning (- 0.034 per month, p = 0.046) products significantly decreased after the implementation of "4 + 7" policy. No significant difference was found for the immediate change of DPI for alternative drugs (p = 0.537), while a significant decrease in change trend was detected in the post-"4 + 7" policy period (- 0.003 per month, p = 0.014). The DPI of the overall policy-related drugs significantly decreased (- 0.261 per month, p < 0.0001) after "4 + 7" policy.
conclusionsThese findings indicate that the price behavior of pharmaceutical enterprises changed under NCDP policy, while the price linkage effect is still limited. It is necessary to further expand the scope of centralized purchased drugs and strengthen the monitoring of related drugs regarding price change and consumption structure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.